Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-02-24

Clinical Trial Update: Ondansetron Augmentation in Treatment-resistant OCD [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating ondansetron augmentation in treatment-resistant obsessive-compulsive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ondansetron (ondansetron)

Snippet

Sponsor: Institute of Neuroscience, Florence, Italy | Conditions: Obsessive Compulsive Disorder | Phase 4 | Status: COMPLETED